HomeAI · summaries
Storia in 2 fonti
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight - Hims & Hers Health (NYSE:HI
Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to a federal compounding list.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
cryptonomist.ch
Azioni HIMS: tre sedute in rosso, CFO vende $229K. Verdetto FDA sui peptidi il 23-24 luglio
Le azioni HIMS di Hims & Hers Health scendono per tre sessioni consecutive. Il mercato attende la decisione FDA sui peptidi il 23-24 luglio 2026.
- ·
benzinga.com
Why Is Hims & Hers Health Stock Surging on Thursday? - Hims & Hers Health (NYSE:HIMS)
Hims & Hers Health Inc (NYSE: HIMS) stock surges Thursday after an FDA advisory committee votes on adding BPC-157 to the allowed pharmacy compounding list.
